Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Royalty Pharma plc (RPD.F)

Compare

30.96

+0.17

+(0.55%)

As of 8:44:38 AM GMT+1. Market Open.

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical r

GlobeNewswire 6 days ago

RPRX
Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Royalty Pharma Plc (NASDAQ:RPRX) stands against the other best performing pharma stocks so far in 2025. What’s Going on in the Pharma Sector? On February 20, Jared […]

Insider Monkey 10 days ago

RPRX
Royalty Pharma Announces R&D Funding Collaboration With Biogen

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept

GlobeNewswire 22 days ago

RPRX
Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

Royalty Pharma PLC (RPRX) reports robust growth in 2024 with a new $3 billion share repurchase plan and strategic portfolio expansions.

GuruFocus.com 22 days ago

RPRX
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $594 million. Its GAAP profit of $0.57 per share was significantly above analysts’ consensus estimates.

StockStory 22 days ago

RPRX
Royalty Pharma Reports Q4 and Full Year 2024 Results

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in Q4 2024 and $2,769 million for FY 2024Full year 2025 guidance: Portfolio Receipts expected to be $2,900 to $3,050 million excluding future transactions NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2

GlobeNewswire 22 days ago

RPRX
Royalty Pharma Earnings: What To Look For From RPRX

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for.

StockStory 23 days ago

PFE

CELG-RT

RPRX
Is Now The Time To Put Royalty Pharma (NASDAQ:RPRX) On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Simply Wall St. 24 days ago

RPRX
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This pa

GlobeNewswire last month

RPRX
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference

GlobeNewswire last month

RPRX
Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now?

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of […]

Insider Monkey last month

RPRX
Royalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks Now

We recently compiled a list of the 14 Best 52-Week High Stocks To Buy According to Analysts. In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against the other stocks. After two years of substantial gains to record highs, exhaustion in the US equity markets is slowly kicking […]

Insider Monkey last month

RPRX
Royalty Pharma (NASDAQ:RPRX) Has Announced That It Will Be Increasing Its Dividend To $0.22

Royalty Pharma plc's ( NASDAQ:RPRX ) periodic dividend will be increasing on the 10th of March to $0.22, with investors...

Simply Wall St. last month

RPRX
Here’s Why Royalty Pharma plc (RPRX) Led This Week’s Rally

We recently published an article titled These 10 Firms Led This Week’s Rally. In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against the other stocks. Ten companies finished stronger this week, outpacing the broader market thanks to a series of catalysts that lifted investor sentiment. On Friday, […]

Insider Monkey last month

RPRX
Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher?

We recently published a list of 10 Firms Close Shortened Trading Week Higher. In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against other firms close shortened trading week higher. Wall Street’s main indices ended the shortened trading week in the red territory on Friday after labor […]

Insider Monkey last month

COMP

RPRX
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming events, including Phase 3 results for pelacarsen Royalty Pharma to benefit from new product launches in 2025, including Servier’s Voranigo, Bristol Myers Squibb’s Cobenfy, Ascendis’ Yorvipath, Syndax and Incyte’s Niktimvo and Geron’s Rytelo NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Ro

GlobeNewswire last month

RPRX
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsSimplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of s

GlobeNewswire last month

RPRX
Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buy

GlobeNewswire last month

RPRX
Jim Cramer on Royalty Pharma plc (RPRX): ‘Disappointing Stock, Man, I Can’t Believe It’

We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against the other stocks Jim Cramer talked about. Jim Cramer, host of Mad Money, recently shared some investment wisdom drawn from his four decades of […]

Insider Monkey 2 months ago

RPRX
Royalty Pharma plc (NASDAQ:RPRX) is favoured by institutional owners who hold 72% of the company

Key Insights Institutions' substantial holdings in Royalty Pharma implies that they have significant influence over the...

Simply Wall St. 2 months ago

RPRX

Performance Overview

Return	RPD.F	S&P 500
YTD	+27.89%	-0.66%
1-Year	+18.00%	+14.45%
3-Year	-2.83%	+34.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Royalty Pharma plc (RPD.F)

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025

Royalty Pharma Announces R&D Funding Collaboration With Biogen

Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates

Royalty Pharma Reports Q4 and Full Year 2024 Results

Royalty Pharma Earnings: What To Look For From RPRX

Is Now The Time To Put Royalty Pharma (NASDAQ:RPRX) On Your Watchlist?

Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now?

Royalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks Now

Royalty Pharma (NASDAQ:RPRX) Has Announced That It Will Be Increasing Its Dividend To $0.22

Here’s Why Royalty Pharma plc (RPRX) Led This Week’s Rally

Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher?

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma Announces Dividend Increase

Jim Cramer on Royalty Pharma plc (RPRX): ‘Disappointing Stock, Man, I Can’t Believe It’

Royalty Pharma plc (NASDAQ:RPRX) is favoured by institutional owners who hold 72% of the company

Performance Overview